Lesch-Nyhan disease is a disorder of purine metabolism resulting from mutations in the gene for hypoxanthine guanine phosphoribosyl transferase on the X chromosome. It is characterized by hyperuricemia and all of its consequences, as in gout; but in addition, patients have impressive disease of the central nervous system. This includes spasticity, involuntary movements, and retardation of motor development. The behavioral phenotype is best remembered by self-injurious biting behavior with attendant destruction of tissue. The connection between aberrant metabolism of purines and these neurologic and behavioral features of the disease is not clear. Increasing evidence points to imbalance of neurotransmitters. There is increased excretion of the serotonin metabolite 5-hydroxyindoleacetic acid in the urine. There are decreased quantities and activities of a number of dopaminergic functions. Positron emission tomography scanning has indicated deficiency in the dopamine transporter.
Lesch-Nyhan disease is an inborn error of purine metabolism that has caught the imagination of a number of physicians and scientists. Initial excitement was relevant to the facts that a well defined defect in a single enzyme represented not only the first molecular disorder of purine metabolism to be recognized, but the first biochemical explanation for at least a subset of patients with symptoms of gout and the other effects of hyperuricemia. However, even casual observation of patients with this disease provides a much larger sphere of interest in terms of potential chemical understanding of cerebral function. From the beginning we were impressed by the idea that this was an opportunity to define the manner in which a distinct abnormality in biochemistry could lead to stereotyped patterns of neurologic disease and abnormal behavior. The disease was described over 30 years ago (1) . The promise is still there. Many questions have been answered, but many remain to be elucidated.
Lesch-Nyhan disease is caused by deficient activity of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) (2) . This enzyme normally catalyzes the conversion of hypoxanthine and guanine to their respective nucleotides, inosinic acid (IMP) and guanylic acid (GMP). This leads to enormous overproduction of purine nucleotides via increased, and there are abnormal movements such as chorea and athetosis, as well as dystonia. None of these patients has learned to walk and most require assistance in sitting. The usual appearance of a patient with this disease is in a narrow form-fitting wheelchair supported by a seat belt and a belt around the chest that permits the patient to participate in the world around him. Most patients display considerably more cognitive ability than the motor defect would imply. Most have speech, and a few have even had normal intelligence based on testing. At least one of our patients has succeeded in a normal school curriculum. Two patients have graduated from high school. The testing of intelligence is so complicated by the behavior of these patients that most testing is doubtless inaccurate. A patient who, when presented with written words or images on pages, cannot resist an urge to tear them out of the book or throw them on the floor or at the examiner makes for a difficult test object. These behavioral features of the disease are uniform in the classic disease. The best known of these manifestations is the selfinjurious behavior; the most common of these behaviors is biting, which leads to loss of tissue around the lip and partial amputation of the tongue. Those who do not bite themselves tend to indulge in other self-injurious behaviors, such as head-banging or bruising the chin on a hard surface. These patients have normal pain sensation and regularly display evidence of this when they injure themselves. They sleep poorly and often keep the entire family awake until methods are developed for protection against mutilation when family members are asleep. Patients In the same study, data on norepinepherine and serotonin function were not significantly different in the brains of the patients. The activity of dopamine 3-hydroxylase was not decreased in the hypothalamus, and that is significant because alterations in this enzyme have previously been reported in the plasma of some patients. The levels of serotonin were slightly increased and significantly so in the putamen. 5-Hydroxyindolacetic acid was also elevated there, as well as in the pallidum, so these data were consistent with our findings in the urine of patients with this disease. The data on serotonin and norepinepherine highlight the specificity of the observations on dopaminergic function.
Similarly, we studied the concentrations of HVA in the cerebrospinal fluid in a patient with this disease and found that the level was low (9) . A more elaborate study was reported by Silverstein et al. (10) . They pointed out that concentrations in cerebrospinal fluid of HVA and 5-hydroxyindolacetic acid undergo age-related changes. There is a rapid fall in the first 3 years of life and then a more gradual fall through adolescence. Accordingly, they did serial measurements of cerebrospinal fluid HVA in 4 patients over a 5-year period with an age range of 1.5-17 years, and they compared these data with age-related data on 94 controls. The values for the Lesch-Nyhan patients were lower than the mean for age in 18 of 19 samples tested, and 10 samples fell below the range found in controls.
The hypothesis that dopamine is related to self-injurious behavior received support by the development of a rat model by Breese et al. (11) . They used 6-hydroxydopamine (6-OHDA), which destroys catecholaminecontaining neurons in the brain. Treatment of adult animals makes them sensitive to a number of behaviors on the administration of dopa or a dopa agonist. Treatment of newborn animals leads to self-injurious behavior in response to a dopa agonist. This change in sensitivity was a long-lasting effect of neonatal treatment with 6-OHDA. As long as that compound was given in the neonatal period, the dopa agonist could be given even in adulthood and the self-injurious response was observed. In one series, 0 of 20 control animals exhibited dopa-induced self-injurious behavior. Similarly, 0 of 18 animals given 6-OHDA as adults, and 39 of 60 treated in the neonatal period with 6-OHDA, exhibited self-injurious behavior, a highly significant difference. There were also dose-effect relationships. In the neonatally treated animals, the greater the dose of dopa or dopa agonist, the greater the percentage of animals exhibiting self-injurious behavior.
Breese et al. (11) conducted pharmacological studies in which D2 or mixed DI-D2 receptor antagonists such as haloperidol and flupentixol had some effect in blocking the self-injurious response to dopa. On the other hand, there was virtually complete inhibition of this response when the Dl antagonist Sch-23390 was used. Unfortunately, to date none of the D1 or D2 antagonists that have been used in Lesch-Nyhan patients have been effective in the management of their selfinjurious behavior.
Other Disease Models
The basal ganglia are increasingly recognized as a target for the adverse effects of metabolic disease. Haas et al. (12) reported experience with an 8-year-old girl with propionic acidemia who was in excellent metabolic control, and was in hospital after receiving intensive treatment for pancreatitis such that her levels of the abnormal metabolites in the urine were lower than they had ever been. Nevertheless, as she was being prepared for discharge she became suddenly aphasic, experienced complete infarction of her basal ganglia, and died within a few days. A review of our only other patient on whom an autopsy had been done after death from propionic acidemia revealed lesions in the basal ganglia in which there was neuronal loss.
More recently, we reported (13) on two other patients in whom propionic acidemia had a more indolent presentation than in the usual patient (the usual patient has acute life-threatening episodes of ketoacidosis that at least call attention to the disease). These patients instead presented first neurologically. On first examination, one of the patients appeared to be a typical Lesch- Nyhan patient. He was wheelchair-bound and had a combination of athetoid and dystonic movements that were typical of his basal ganglia disease. However, he had no abnormalities in behavior and his metabolic disease appeared to be static at that time. We had not seen the second patient, although a diagnosis of propionic acidemia was made for the first time after the age of 20. Our first encounter with the second patient was a blood sample that was sent to the laboratory for HPRT analysis because he not only had a diagnosis of athetoid cerebral palsy, but he had destructively bitten his lower lip. The HPRT was normal, and we suggested sending blood and urine for further metabolic studies. Further studies found methylcitrate and the other organic acids typical of propionic acidemia, and enzymatic analysis revealed a severe deficiency of propionyl CoA carboxylase.
In seeking models for abnormalities in dopaminergic systems we have begun to look at patients with abnormalities in biopterin synthesis (14) . Patients with these abnormalities first became recognized with the programs of neonatal screening for phenylketonuria. It became apparent that there was a subset of patients uncovered by neonatal screening programs that, despite excellent compliance with the diet and normal levels of phenylalanine after treatment, went on to develop severe mental retardation. A number of these disorders reflect various steps in the synthesis of tetrahydrobiopterin or BH4, which is the essential cofactor of the phenylalanine hydroxylase reaction (14) . The importance from the dopamine point of view is that BH4 is also the cofactor for the tyrosine hydroxylase reaction in the synthesis of dopa, and, hence, dopamine. In the first step of this reaction, the guanosine triphosphate (GTP) reaction is severely deficient in patients homozygous for mutations in A relationship between deficiency of HPRT and its potential shortages of IMP and GMP and its di-and tri-nucleotides could be through a requirement for GTP in signal transduction through the dopamine receptor-agonist interaction (16) (17) (18) . Alternatively, there could be defective synthesis of tetrahydrobiopterin, as in the GTP cyclohydrolase deficiency dopa-responsive dystonia, leading to a shortage of dopamine in the basal ganglia.
In summary, there is substantial evidence relevant to dopamine and the Lesch-Nyhan disease. I am hopeful that with time we will be able to make the appropriate connections between neurotransmitter interrelations and mutation in the HPRTgene. I am hopeful that all of this will lead to a more effective means of treatment in Lesch-Nyhan disease.
